Background Intolerably high doses of systemic corticosteroids and additional
immunosuppressants may be required to control disease activity in autoimmune bullous skin …

Background Bullous pemphigoid (BP) is the most common autoimmune blistering disease
requiring treatment with immunosuppressive medications; however, finding a therapy that …

The objective of this review was to critically analyze the currently available literature on the
use of rituximab to treat patients with bullous pemphigoid (BP). The focus was to highlight …

Autoimmune blistering diseases are associated with autoantibodies to desmosomal
(pemphigus group) or hemidesmosomal proteins (autoimmune subepidermal blistering …

BACKGROUND: Rituximab has been increasingly used in autoimmune blistering
dermatoses, mainly in pemphigus. However, only a few larger case series are available on …

Background Rituximab, a monoclonal antibody directed against B lymphocytes, has been
found to be a therapeutic agent for severe, refractory autoimmune bullous diseases …

BACKGROUND: Rituximab induces depletion of B cells and has shown efficacy in antibody-
mediated autoimmune disorders. In studies on small series of patients with pemphigus …

Treatment of autoimmune blistering diseases consists of systemic glucocorticosteroids
usually in combination with additional immunosuppressants such as azathioprine and …

First‐line combination therapy with rituximab and corticosteroids provides a high complete
remission rate in moderate‐to‐severe bullous pemphigoid | British Journal of Dermatology …

Background Pemphigus is a severe autoimmune blistering disorder caused by
autoantibodies to desmoglein 1 and 3. The disease course is typically severe, thus requiring …